This is a prospective study that will assess the impact of MammaPrint on chemotherapy + endocrine versus endocrine alone treatment decisions in patients with an Oncotype Intermediate Score.
The frequency of chemotherapy + endocrine versus endocrine alone decisions in Oncotype DX intermediate score patients will be calculated before and after receiving the MammaPrint result.
Study Type
OBSERVATIONAL
Enrollment
820
All subjects
Difference in recommended adjuvant chemotherapy treatment
The frequency of chemotherapy + endocrine versus endocrine alone decisions in Oncotype DX intermediate score patients will be calculated before and after receiving the MammaPrint result. A Chi-square test will be performed for the comparison of the two proportions.
Time frame: 30 days
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Maricopa Integrated Health System
Phoenix, Arizona, United States
Providence Saint Joseph Medical Center
Burbank, California, United States
Comprehensive Cancer Center
Palm Springs, California, United States
Breastlink
Santa Ana, California, United States
Redwood Regional Cancer Center
Santa Rosa, California, United States
Exempla Saint Joseph Hospital
Denver, Colorado, United States
Stamford Hospital
Stamford, Connecticut, United States
The Breast Institute at JFK Medical
Atlantis, Florida, United States
Halifax Health Center for Oncology
Daytona Beach, Florida, United States
Broward Health Medical Center
Fort Lauderdale, Florida, United States
...and 43 more locations